IBM Retirement Fund lowered its stake in shares of Eli Lilly And Co (NYSE:LLY) by 13.3% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 20,030 shares of the company’s stock after selling 3,067 shares during the period. IBM Retirement Fund’s holdings in Eli Lilly And Co were worth $1,709,000 as of its most recent SEC filing.
Several other large investors also recently modified their holdings of the business. Greenleaf Trust lifted its stake in shares of Eli Lilly And Co by 37.7% in the 2nd quarter. Greenleaf Trust now owns 9,815 shares of the company’s stock valued at $838,000 after purchasing an additional 2,686 shares during the last quarter. Van ECK Associates Corp lifted its stake in shares of Eli Lilly And Co by 10.8% in the 1st quarter. Van ECK Associates Corp now owns 587,502 shares of the company’s stock valued at $45,455,000 after purchasing an additional 57,487 shares during the last quarter. IFM Investors Pty Ltd lifted its stake in shares of Eli Lilly And Co by 44.1% in the 2nd quarter. IFM Investors Pty Ltd now owns 44,529 shares of the company’s stock valued at $3,800,000 after purchasing an additional 13,637 shares during the last quarter. Private Asset Management Inc. acquired a new stake in shares of Eli Lilly And Co in the 2nd quarter valued at $1,206,000. Finally, Hedeker Wealth LLC acquired a new stake in shares of Eli Lilly And Co in the 2nd quarter valued at $213,000. 76.55% of the stock is owned by institutional investors.
Several research firms recently issued reports on LLY. BMO Capital Markets reaffirmed a “hold” rating and issued a $78.00 price objective on shares of Eli Lilly And Co in a research note on Thursday, May 10th. TheStreet raised shares of Eli Lilly And Co from a “c+” rating to a “b” rating in a research note on Friday, June 29th. Zacks Investment Research raised shares of Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $100.00 price objective for the company in a research note on Wednesday, July 18th. Bank of America boosted their target price on shares of Eli Lilly And Co from $90.00 to $94.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 25th. Finally, Cantor Fitzgerald boosted their target price on shares of Eli Lilly And Co from $100.00 to $110.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 25th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and eleven have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $100.13.
In other news, insider Donald A. Zakrowski sold 600 shares of the business’s stock in a transaction dated Tuesday, September 4th. The shares were sold at an average price of $105.57, for a total transaction of $63,342.00. Following the transaction, the insider now owns 3,530 shares in the company, valued at approximately $372,662.10. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Daniel Skovronsky acquired 10,000 shares of the company’s stock in a transaction dated Thursday, June 14th. The shares were bought at an average price of $86.22 per share, for a total transaction of $862,200.00. The disclosure for this purchase can be found here. In the last 90 days, insiders have sold 1,732,813 shares of company stock worth $168,655,414. Insiders own 0.11% of the company’s stock.
NYSE:LLY opened at $104.62 on Wednesday. Eli Lilly And Co has a 52-week low of $73.69 and a 52-week high of $106.49. The company has a current ratio of 1.40, a quick ratio of 1.09 and a debt-to-equity ratio of 0.79. The stock has a market cap of $113.47 billion, a PE ratio of 24.44, a P/E/G ratio of 1.76 and a beta of 0.27.
Eli Lilly And Co (NYSE:LLY) last posted its quarterly earnings data on Tuesday, July 24th. The company reported $1.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.30 by $0.20. Eli Lilly And Co had a negative net margin of 0.60% and a positive return on equity of 39.84%. The company had revenue of $6.36 billion for the quarter, compared to the consensus estimate of $6.05 billion. During the same quarter in the previous year, the firm posted $1.11 EPS. The business’s revenue was up 9.1% compared to the same quarter last year. research analysts expect that Eli Lilly And Co will post 5.47 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Monday, September 10th. Stockholders of record on Wednesday, August 15th will be issued a dividend of $0.5625 per share. The ex-dividend date of this dividend is Tuesday, August 14th. This represents a $2.25 annualized dividend and a dividend yield of 2.15%. Eli Lilly And Co’s payout ratio is 52.57%.
Eli Lilly And Co Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Recommended Story: Closed-End Mutual Funds
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.